99856-75-4

Basic information

• Product Name: 1-(thiophen-2-yl)cyclohexanecarbonitrile
• Synonyms: 1-(thiophen-2-yl)cyclohexanecarbonitrile
• CAS NO: 99856-75-4
• Molecular Weight: 191.297
• Mol File: 99856-75-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-(thiophen-2-yl)cyclohexanecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(thiophen-2-yl)cyclohexanecarbonitrile(99856-75-4)
• EPA Substance Registry System: 1-(thiophen-2-yl)cyclohexanecarbonitrile(99856-75-4)

Safety Data

• Hazardous Substances Data: 99856-75-4(Hazardous Substances Data)

Upstream product

• 20893-30-5 2-cyanomethylthiophene 
• 111-24-0 1,5-dibromo-pentane 
• 628-77-3 1,5-diiodopentane 

Downstream Products

• 167984-83-0 1-[2]thienyl-cyclohexanecarboxylic acid ethyl ester 
• 100058-72-8 1-(thiophen-2-yl)cyclohexanecarboxylic acid 
• 109840-79-1 5-(1-thiophen-2-yl-cyclohexyl)-1⁽²⁾H-tetrazole 
• 1429308-69-9 9a'-phenyl-7',8',9',9a'-tetrahydro-5'H-spiro[cyclohexane-1,4'-thieno[2,3-g]indolizin]-5'-one 
• 767627-74-7 C-(1-thiophen-2-ylcyclohexyl)methylamine 
• 99858-96-5 1-Thien-2-yl-cyclohexan-1-carbonsaeureamid 

Relevant articles and documents

AMIDE DERIVATIVES COMPRISING HETEROCYCLOALKYL RING

PROBLEM TO BE SOLVED: To provide compounds or pharmacologically acceptable salts thereof that have excellent EP300 and/or CREBBP histone acetyltransferase inhibitory activity. SOLUTION: The invention provides compounds represented by the formula (1) in the figure or pharmacologically acceptable salts thereof. (In the formula (1), ring Q1, ring Q2, ring Q3, X and L are as defined in the specification.) SELECTED DRAWING: None COPYRIGHT: (C)2020,JPO&INPIT

A cascade approach to fused indolizinones through Lewis acid-copper(i) relay catalysis

A relay catalytic cascade process involving Lewis acid triggered ring-opening of cyclopropyl ketones with nitriles, the copper(i)-catalyzed Ritter process, and acid-promoted N-acyliminium ion cyclization is described, which efficiently provides thieno-, furano-, and benzo-indolizinones in moderate to good yields. The Royal Society of Chemistry 2013.

CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.